Walter Ling, M.D., is Professor of Psychiatry and Founding Director of the Integrated Substance Abuse Programs (ISAP) at UCLA, one of the foremost substance abuse research groups in the United States and worldwide. He is board certified in neurology and psychiatry, is active in research and clinical work, and has been listed in "Best Doctors in America," "Best Doctors in the West," and "Best Doctors in Los Angeles." Dr. Ling's research in pharmacotherapy for opioid addiction provided pivotal information for the approval of LAAM, naltrexone, and buprenorphine. His research projects have included investigations of medications for the treatment of opioid, cocaine, methamphetamine, and cannabis use disorders, opioid-induced hyperalgesia, and treatment of pain in opioid-maintained patients. Dr. Ling has extended ISAP's research beyond the United States to Asia and the Middle East, and he has led or participated in international training efforts in 15 countries to advance addiction medicine and addiction research. As Principal Investigator of the Pacific Region Node of the NIDA Clinical Trial Network (CTN), Dr. Ling most recently completed a multi-site clinical trial using a medication combination of extended-release naltrexone with daily bupropion for the treatment of methamphetamine use disorders. This project used a novel stepped approach for and enhanced methods for confirming medication adherence including daily dosing videos captured with Smartphones sent by study participants to the study team. Dr. Ling's current and future research projects will continue to examine potential and promising methods for the treatment of substance use disorders.